Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex™)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006915/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study is being carried out to see if treatment with ZD1839 (Gefitinib) combined with
Arimidex (Anastrozole) has improved efficacy over Arimidex alone in preventing progression of
metastatic breast cancer.
提供机构：
Vivli
创建时间：
2021-04-16
